Current Report Filing (8-k)
24 February 2017 - 9:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported):
February 23, 2017
Immunomedics, Inc.
|
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
|
000-12104
|
|
61-1009366
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
300 The American Road, Morris Plains, New Jersey
|
|
07950
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(973) 605-8200
|
(Registrant’s telephone number, including area code
|
Not applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other events
On February 23, 2017, Immunomedics, Inc. issued
a press release titled “Immunomedics Announces Company’s Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of
T-Cell-Redirecting Bispecific Antibodies.” The full text of the press release is attached to this current report on Form 8-K
as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements
and Exhibits.
(d) Exhibits.
Exhibit
No.
|
|
Description
of Exhibit
|
99.1
|
|
Press Release of Immunomedics, Inc., dated February 23, 2017, titled “Immunomedics Announces Company’s Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies”
|
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
IMMUNOMEDICS, INC.
|
|
|
|
By:
|
/s/ Michael R. Garone
|
|
|
Name: Michael R. Garone
Title: Vice President, Finance and
Chief Financial Officer
|
Date:
February 23, 2017
Exhibit Index
Exhibit
Number
|
|
Description
|
99.1
|
|
Press Release of Immunomedics, Inc., dated February 23, 2017, titled “Immunomedics Announces Company’s Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies”
|
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2024 to May 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Immunomedics Inc (NASDAQ): 0 recent articles
More Immunomedics Inc News Articles